Incretin-driven weight loss directly shrinks fast-food portions and expands apparel sales.
The scaling adoption of GLP-1 drugs has reached a critical mass that actively depresses fast-food portion sizes while driving double-digit wardrobe replacement sales.
The same conclusion keeps arriving from across the workspace's research — 3 topics independently instantiate this theme. Filter the evidence by where it came from:
A population-level reduction in adult obesity rates demonstrates that the scale of GLP-1 adoption has reached a critical mass.
It shows a direct macro-level increase in US apparel spending as a result of GLP-1 adoption forcing wardrobe replacements.
The Cornell household data quantifies the demand shrinkage that chains from KFC to Olive Garden are answering with smaller portions and protein-forward menus.
McDonald's engineering portion options around GLP-1 users shows the incretin class directly rewriting fast-food order design.
Both halves of the law surface in one cycle: fast-food spending cuts alongside an apparel-spend uplift driving analyst upgrades and downgrades.
GLP-1 demand destruction is now priced at brand level across the snack complex, extending the incretin consumption shock into packaged food.
The consumption shock documented in fast food and apparel now appears as a quantified grocery and snack demand decline among GLP-1 households.